Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial (2019)

First Author: Clamp A
Attributed to:  CANCER: Trials with potential global reach and other challenging trials funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(19)32259-7

PubMed Identifier: 31791688

Publication URI: http://europepmc.org/abstract/MED/31791688

Type: Journal Article/Review

Parent Publication: The Lancet

Issue: 10214

ISSN: 0140-6736